UroToday3d
The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.
Aggressive variant prostate cancer (AVPC) is characterized by a molecular signature involving combined defects in TP53, RB1, and/or PTEN (AVPC-TSGs), identifiable through immunohistochemistry or ...
UroToday3d
Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128).
Surgery remains the cornerstone of localized renal cell carcinoma (RCC) care. Pembrolizumab has recently been recommended as a standard of care for RCC patients who are at high risk of recurrence.
UroToday3mon
Prostate Cancer
Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System. January 7, 2025 Prostate Cancer Patient With Lymph-node Metastasis Treated Only With ...
UroToday3d
Cost-utility analysis of MR imaging-guided transurethral ultrasound ablation for the treatment of low- to intermediate-risk localised prostate cancer.
Magnetic resonance-guided transurethral ultrasound ablation (MR-TULSA) is a new focal therapy for treating localised prostate cancer that is associated with fewer adverse effects (AEs) compared with ...
UroToday3d
Immediate second resection versus restage transurethral resection of bladder tumor: A prospective randomized clinical trial (IMMERSE trial).
The role of repeat transurethral resection of bladder tumor (TURBT) for the management of nonmuscle invasive bladder carcinoma is debated, especially when initial resections include detrusor muscle.
UroToday3d
Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI.
PSMA-PET is a reference standard examination for patients with prostate cancer, but even using recently introduced digital PET detectors image acquisition with standard field-of-view scanners is still ...
UroToday3d
An Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER Consortium.
Patient-reported outcome measures (PROMs) are increasingly being used to capture the patients' perspective of their functional status and quality of life (QoL). Big data can help us better understand ...
UroToday4d
Increased Translation Driven by Non-Canonical EZH2 Creates a Synthetic Vulnerability in Enzalutamide-Resistant Prostate Cancer - Beyond the Abstract
Prostate cancer (PC) treatment remains a challenge, particularly in its advanced, castration-resistant form (CRPC), where resistance to androgen receptor (AR)-targeted therapies, such as enzalutamide ...
UroToday5d
The associations among platelet count, mean platelet volume, and erectile dysfunction: an observational and Mendelian randomization study.
While previous studies have explored the associations and causalities among platelet count (PC), mean platelet volume (MPV), and erectile dysfunction (ED), further investigations are needed to clarify ...
UroToday4d
Late Side Effects of Testicular Cancer and Treatment: A Comprehensive Review - Beyond the Abstract
In the last couple of decades, we have witnessed an increase in the incidence of cancer worldwide, particularly in Western Europe and the United States. Fortunately, this trend is accompanied by ...
UroToday4d
The Outcomes of Onco-Testis Sperm Extraction at the Time of Radical Orchiectomy.
To evaluate outcomes of onco-testis sperm extraction (TESE) and to define potential predictors of successful surgical sperm retrieval (SSR). For this study, we examined all men (i) diagnosed with a ...
UroToday4d
Belzutifan for renal cell carcinoma: Balancing regulatory approval with societal and patient impact.
LITESPARK-005 evaluated belzutifan against everolimus in advanced renal cell carcinoma (RCC),1 demonstrating significant progression-free survival improvement but failing to meet the overall survival ...